Ulf Wiinberg appointed new CEO of Lundbeck

The Supervisory Board of H. Lundbeck A/S has today appointed Ulf
Wiinberg as new president and CEO of Lundbeck. Ulf Wiinberg will take
up his new position on 1 June 2008."I am very pleased to announce that Ulf Wiinberg will join Lundbeck
as president and CEO," says Per Wold-Olsen, Chairman of Lundbeck's
Supervisory Board.
 
Ulf Wiinberg will be leaving the US pharmaceutical company Wyeth,
where he has been responsible for two areas: Strategic oversight of
Wyeth's biopharma activities and as President of Wyeth Europe, Middle
East, Africa and Canada - the latter division generates revenues of
approximately DKK 30 billion (USD 6 billion) and employs 5,200
people.
 
Lundbeck's future president and CEO started his pharmaceutical career
in Sweden in 1981 and has worked for Wyeth for 27 years, where he has
held management positions in Europe as well as in the USA. Ulf
Wiinberg distinguishes himself by his strong commercial competencies
and has achieved a number of significant results at Wyeth.
 "Ulf Wiinberg is uniquely qualified to handle the challenges that
Lundbeck faces in the short term, and with his broad experience he
can contribute to meeting the strategic challenges that we face in
the long term," says Per Wold-Olsen.
 
Ulf Wiinberg was previously responsible for Wyeth Consumer Healthcare
Products and Managing Director of Wyeth in the UK. Ulf Wiinberg has
served as a member of Wyeth's management committee as well as of the
corporation's operations committee, legal committee and HR committee.
 
Ulf Wiinberg is 49 years old, married and has four children. He is a
Danish citizen who was born and raised in Sweden, and has lived and
worked for five years in the UK and 13 years in the USA. In
connection with his new position, Ulf Wiinberg will move to Denmark
from New Jersey, USA.
 "Lundbeck is a very interesting company with a focused strategy
within diseases of the central nervous system. It is an area where
there unfortunately is a vast need for innovation and progress in the
treatment of a number of diseases, as many patients do not currently
have access to adequate treatment," says Ulf Wiinberg.
 "As a previous competitor I know that Lundbeck has a good reputation
and is acknowledged as company with great strengths within research
and development and for being very good at sales and marketing. I am
convinced that the energy and competency within the company will
enable us to set new standards for patients and for Lundbeck," says
Ulf Wiinberg.
 
There will be a press conference at Lundbeck's address above on 29
April at 2pm. Journalists and capital market stakeholders are
welcome. The meeting will be conducted in English.
 
Lundbeck contacts
 

Investors:                 Media:
                            
Jacob Tolstrup             Jens Højbjerg
Director                   Media Relations Manager
+45 36 43 30 79            +45 36 43 28 33
                            
Palle Holm Olesen           
Head of Investor Relations  
+45 36 43 24 26             

 
Stock Exchange Release No 337 - 29 April 2008
 
About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2007,
the company's revenue was DKK 11 billion (approximately EUR 1.5
billion or USD 2.0 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com